Skip to main content

Universal healthcare coverage for first episode of schizophrenia-spectrum disorders in Chile: analysis of the administrative database

Abstract

Aim of the study was to analyse the Ministry of Health’s (MINSAL) administrative database of the Universal Health Coverage (UHC) program for First Episode of Schizophrenia Spectrum Disorders (FEP-SSD). The database included every case registered in the program between 2004 and 2017. According to the timeframes established for permanence in the program, cases were defined as Suspected, FEP in diagnostic observation and FEP-SSD. Only first registers were analysed. We compared gender, age at entry, level of care and region where the case was registered. Denominator data for estimation of incidence rates were obtained from the last census. We adjusted incidence rate ratios by age, gender, and region. During the studied period, 33.207 suspected cases were registered. 27.006 (81%) were confirmed as FEP and after 6-month follow-up, 22.701 (68%) were confirmed as FEP-SSD. The median age at entry was 24 years, males entering at younger age. Male proportion was higher than female in all groups. 46.9% of all cases were detected in primary care. FEP-SSD cases were six years younger and had a higher proportion of males than discarded cases (62.6 vs 53.2%). During 169.4 million person-years at risk, crude incidence for suspected cases was 19.58 per 100.000 person-years; for FEP, 15.92 per 100.000 person-years and for FEP-SSD, 13.38 per 100.000 person-years. Chile has lower incidence of FEP-SSD compared to current world estimations but gender proportions are comparable. This UHC program has allowed early access through the integration of mental health to the health network at all levels of care.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Data availability

The data that support the findings of this study are available from the Ministry of Health, Government of Chile. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of the Ministry of Health, Government of Chile.

References

  1. 1.

    Whiteford HA, Degenhardt L, Rehm J et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586. https://doi.org/10.1016/S0140-6736(13)61611-6

    Article  PubMed  Google Scholar 

  2. 2.

    Lora A, Kohn R, Levav I et al (2012) Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. Bull World Health Organ 90:47-54B. https://doi.org/10.2471/BLT.11.089284

    Article  PubMed  Google Scholar 

  3. 3.

    Jesus Mari J, Tófoli LF, Noto C et al (2013) Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies. Drugs 73:1549–1568. https://doi.org/10.1007/s40265-013-0113-4

    Article  PubMed  Google Scholar 

  4. 4.

    O’Connell T, Rasanathan K, Chopra M (2014) What does universal health coverage mean? Lancet 383:277–279. https://doi.org/10.1016/S0140-6736(13)60955-1

    Article  PubMed  Google Scholar 

  5. 5.

    Patel V (2016) Universal health coverage for schizophrenia: a global mental health priority. Schizophr Bull 42:885–890. https://doi.org/10.1093/schbul/sbv107

    Article  PubMed  Google Scholar 

  6. 6.

    Aguilera X, Castillo-Laborde C, Ferrari MN-D et al (2014) Monitoring and evaluating progress towards universal health coverage in Chile. PLoS Med 11:e1001676. https://doi.org/10.1371/journal.pmed.1001676

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Minoletti A, Soto-Brandt G, Sepúlveda R et al (2018) Mental health response capacity in primary care in Chile: a contribution to Alma-Ata. Revista Panamericana de Salud Pública https://doi.org/10.26633/RPSP.2018.136

  8. 8.

    Salud MD (2004) LEY-19966 03-SEP-2004 MINISTERIO DE SALUD. In: Ley Chile - Biblioteca del Congreso Nacional. https://www.leychile.cl/Navegar?idNorma=229834. Accessed 7 Sep 2017

  9. 9.

    Markkula N, Alvarado R, Minoletti A (2011) Adherence to guidelines and treatment compliance in the Chilean national program for first-episode schizophrenia. PS 62:1463–1469. https://doi.org/10.1176/appi.ps.001042011

    Article  Google Scholar 

  10. 10.

    Ministerio de Salud (2005) Guía Clínica: Para el tratamiento de personas desde el primer episodio de Esquizofrenia

  11. 11.

    Ministerio de Salud (2009) Guía Clínica: Para el tratamiento de personas desde el primer episodio de Esquizofrenia

  12. 12.

    Ministerio de Salud (2017) Guía Clínica: Para el tratamiento de personas desde el primer episodio de Esquizofrenia

  13. 13.

    Goldner EM, Hsu L, Waraich P, Somers JM (2002) Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 47:833–843. https://doi.org/10.1177/070674370204700904

    Article  PubMed  Google Scholar 

  14. 14.

    Vicente B, Kohn R, Rioseco P et al (2006) Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am J Psychiatry 163:1362–1370

    Article  Google Scholar 

  15. 15.

    González-Valderrama A, Jongsma HE, Mena C et al (2020) The incidence of non-affective psychotic disorders in Chile between 2005 and 2018: results from a national register of over 30000 cases. Psychological Med. https://doi.org/10.1017/S0033291720002664

    Article  Google Scholar 

  16. 16.

    World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, Geneva

    Google Scholar 

  17. 17.

    Jablensky A (2010) The diagnostic concept of schizophrenia: its history, evolution, and future prospects. Dialogues Clin Neurosci 12:271–287

    Article  Google Scholar 

  18. 18.

    Davidson LL, Grigorenko EL, Boivin MJ et al (2015) A focus on adolescence to reduce neurological, mental health and substance-use disability. Nature 527:S161–S166. https://doi.org/10.1038/nature16030

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Reinhardt MM, Cohen CI (2015) Late-life psychosis: diagnosis and treatment. Curr Psychiatry Rep. https://doi.org/10.1007/s11920-014-0542-0

    Article  PubMed  Google Scholar 

  20. 20.

    Instituto Nacional de Estadísticas (2019) Censos de Población y Vivienda - Censo 2017. https://www.ine.cl/estadisticas/censos/censos-de-poblacion-y-vivienda. Accessed 28 Aug 2019

  21. 21.

    Vandenbroucke JP, Pearce N (2012) Incidence rates in dynamic populations. Int J Epidemiol 41:1472–1479. https://doi.org/10.1093/ije/dys142

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    I Nacional de Estadisticas (Santiago de Chile) (2008) División político administrativa y censal 2007. Instituto Nacional de Estadísticas, Santiago (Chile)

    Google Scholar 

  23. 23.

    StataCorp (2019) Stata statistical software: release 16. StataCorp LLC., College Station, TX

    Google Scholar 

  24. 24.

    Del-Ben CM, Shuhama R, Loureiro CM et al (2019) Urbanicity and risk of first-episode psychosis: incidence study in Brazil. Br J Psychiatry. https://doi.org/10.1192/bjp.2019.110

    Article  PubMed  Google Scholar 

  25. 25.

    Castillejos MC, Martín-Pérez C, Moreno-Küstner B (2018) A systematic review and meta-analysis of the incidence of psychotic disorders: the distribution of rates and the influence of gender, urbanicity, immigration and socio-economic level. Psychol Med 48:2101–2115. https://doi.org/10.1017/S0033291718000235

    Article  Google Scholar 

  26. 26.

    Jongsma HE, Turner C, Kirkbride JB, Jones PB (2019) International incidence of psychotic disorders, 2002–17: a systematic review and meta-analysis. The Lancet Public Health 4:e229–e244. https://doi.org/10.1016/S2468-2667(19)30056-8

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Eyheramendy S, Martinez FI, Manevy F et al (2015) Genetic structure characterization of Chileans reflects historical immigration patterns. Nat Commun 6:1–10. https://doi.org/10.1038/ncomms7472

    CAS  Article  Google Scholar 

  28. 28.

    Häfner H, Maurer K, Löffler W, Riecher-Rössler A (1993) The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162:80–86. https://doi.org/10.1192/bjp.162.1.80

    Article  PubMed  Google Scholar 

  29. 29.

    Thorup A, Waltoft BL, Pedersen CB et al (2007) Young males have a higher risk of developing schizophrenia: a Danish register study. Psychol Med 37:479. https://doi.org/10.1017/S0033291707009944

    Article  PubMed  Google Scholar 

  30. 30.

    Häfner H (2019) From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: how sex, age, and other risk factors influence incidence and course of illness. Psychiatry Journal https://www.hindawi.com/journals/psychiatry/2019/9804836/. Accessed 7 Sep 2020

  31. 31.

    Jongsma HE, Gayer-Anderson C, Lasalvia A et al (2018) Treated incidence of psychotic disorders in the multinational EU-GEI study. JAMA Psychiat 75:36. https://doi.org/10.1001/jamapsychiatry.2017.3554

    Article  Google Scholar 

  32. 32.

    Patel V, Saxena S (2019) Achieving universal health coverage for mental disorders. BMJ 366:l4516. https://doi.org/10.1136/bmj.l4516

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Inter-American Drug Abuse Control Commission (2019) Informe sobre el consumo de drogas en las Américas, 2019 / Comisión Interamericana para el Control del Abuso de Drogas

  34. 34.

    Observatorio Chileno de Drogas, Servicio Nacional para la Prevención y Rehabilitación del Consumo de Drogas y Alcohol, SENDA, Gobierno de Chile (2018) Décimo Segundo Estudio Nacional de Drogas en Población Escolar de Chile, 2017 8o Básico a 4o Medio

  35. 35.

    Marconi A, Di Forti M, Lewis CM et al (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42:1262–1269. https://doi.org/10.1093/schbul/sbw003

    Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Di Forti M, Quattrone D, Freeman TP et al (2019) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 6:427–436. https://doi.org/10.1016/S2215-0366(19)30048-3

    Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Anderson KK, Fuhrer R, Malla AK (2010) The pathways to mental health care of first-episode psychosis patients: a systematic review. Psychol Med 40:1585–1597. https://doi.org/10.1017/S0033291710000371

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Fett A-KJ, Lemmers-Jansen ILJ, Krabbendam L (2019) Psychosis and urbanicity. Curr Opin Psychiatry 32:232–241. https://doi.org/10.1097/YCO.0000000000000486

    Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76. https://doi.org/10.1093/epirev/mxn001

    Article  PubMed  Google Scholar 

  40. 40.

    Anderson KK (2013) Health service registry data in psychiatric epidemiology: challenges for definition and interpretation: an editorial comment to: Okkels et al’.s ‘Changes in the diagnosed incidence of early onset schizophrenia over four decades’ (1). Acta Psychiatr Scand 127:9–10. https://doi.org/10.1111/j.1600-0447.2012.01916.x

    Article  PubMed  Google Scholar 

  41. 41.

    Anderson KK (2019) Towards a public health approach to psychotic disorders. Lancet Public Health 4:e212–e213. https://doi.org/10.1016/S2468-2667(19)30054-4

    Article  PubMed  Google Scholar 

  42. 42.

    Hogerzeil SJ, van Hemert AM (2019) Design choices when estimating the treated incidence of schizophrenia. Psychol Med. https://doi.org/10.1017/S0033291719001338

    Article  PubMed  Google Scholar 

  43. 43.

    Möller H-J (2009) Standardised rating scales in Psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 10:6–26. https://doi.org/10.1080/15622970802264606

    Article  PubMed  Google Scholar 

  44. 44.

    Williams J, Farmer AE, Ackenheil M et al (1996) A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. Psychol Med 26:775–783. https://doi.org/10.1017/S003329170003779X

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Parnas J (2015) Differential diagnosis and current polythetic classification. World Psychiatry 14:284–287. https://doi.org/10.1002/wps.20239

    Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Rasmussen AR, Nordgaard J, Parnas J (2020) Schizophrenia-spectrum psychopathology in obsessive–compulsive disorder: an empirical study. Eur Arch Psychiatry Clin Neurosci 270:993–1002. https://doi.org/10.1007/s00406-019-01022-z

    Article  PubMed  Google Scholar 

  47. 47.

    Zandersen M, Parnas J (2020) Exploring schizophrenia spectrum psychopathology in borderline personality disorder. Eur Arch Psychiatry Clin Neurosci 270:969–978. https://doi.org/10.1007/s00406-019-01039-4

    Article  PubMed  Google Scholar 

  48. 48.

    Freudenreich O, Schulz SC, Goff DC (2009) Initial medical work-up of first-episode psychosis: a conceptual review. Early Interv Psychiatry 3:10–18. https://doi.org/10.1111/j.1751-7893.2008.00105.x

    Article  PubMed  Google Scholar 

  49. 49.

    Lieberman JA, First MB (2018) Psychotic Disorders. N Engl J Med 379:270–280. https://doi.org/10.1056/NEJMra1801490

    CAS  Article  PubMed  Google Scholar 

Download references

Funding

Authors are paid staff of Universidad Andres Bello (VL, LV, GV), MINSAL (MI, VH, RC) and Universidad de Santiago (IR), and received no specific funding for this study.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Verónica Larach.

Ethics declarations

Conflict of interest

The authors declare that they do not have any conflict of interest.

Ethical approval

The Research Bioethics Committee of Universidad Andres Bello granted permission to conduct the study (Certificate of Approval 020/2019).

Informed consent for publication

All authors have consented to publish this research report.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Larach, V., Varela, L.F., Vergara, G. et al. Universal healthcare coverage for first episode of schizophrenia-spectrum disorders in Chile: analysis of the administrative database. Eur Arch Psychiatry Clin Neurosci (2021). https://doi.org/10.1007/s00406-021-01254-y

Download citation

Keywords

  • Epidemiology
  • Universal health coverage
  • First episode
  • Schizophrenia
  • Psychosis